ARTIS Ventures’ Post

🚀 One-shot design of a differentiated BRD9 inhibitor using the QuanMol ReDefine platform Bromodomain-containing protein 9 (BRD9), a promising therapeutic target in cancer treatment, has been the focus of many discovery programs, including published works by Boehringer Ingelheim, GSK, AstraZeneca, and Genentech, among others. Due to its compact protein structure, developing novel inhibitors for BRD9 with a high potency poses significant challenges. QuanMol’s one-shot de novo design of a novel BRD9 inhibitor sets a new standard of in silico discovery with: ■ 60 nM Potency: Validated by SPR, this represents a significant advancement over the usual micromolar activity found in virtual screenings and is even more potent than some advanced compounds. ■ Unique Scaffold & Binding Mode: Our approach introduces a novel chemical structure with differentiated binding interactions. ■ Highly Efficient Precision Design: Created precisely in just one attempt and within two hours, demonstrating our platform's capability to significantly accelerate drug discovery. At QuanMol, we aim to narrow the translational gap in small-molecule therapeutics across the industry, enhancing your R&D efficiency with our discovery solutions. This achievement with BRD9 is a testament to our mission and the capability of the AI-powered QuanMol ReDefine platform. Interested in a partnership? Let's connect at connect@quanmol.com. #biotech #pharma #ai #drugdiscovery #drugdesign #biology #quanmol #quanmoltech

Interesting article about the work being done by Enlaza Therapeutics developing covalent biologics for enhanced cancer treatments with fewer side effects. Seems like something that has a lot of potential - interested to see where they go with this! #Oncology #Innovation #HealthcareEvolution #Biotech #Biotechnology

SEED inks research collaboration with Eisai to discover and develop novel molecular glue degraders for neurodegeneration and oncology indications

#ADCs Unlock the potential of Antibody-Drug Conjugates (ADCs) with DimaBio! Dive into the world of cutting-edge biotechnology and discover how #ADCs are revolutionizing #targeted #therapy in our latest blog article: "Navigating the ADC Frontier: Unleashing the Magic of Antibody-Drug Conjugates." Explore the science behind these innovative treatments and learn about their promising future in oncology and beyond. Click the link below to read more! https://lnkd.in/e3uSyWBZ #DimaBio #ADC #Biotechnology #Innovation #Science #Healthcare #TargetedTherapy

Japanese science has long been first class, from developing statins to pioneering cancer immunotherapy and cell therapeutics. But Japan has failed to turn that research into a steady stream of globally successful biotech start-ups because it lacks an ecosystem in which startups can achieve their full potential. Many of the issues are summarized well in this Nature article. That said, ANV believes the tides are changing and many initiatives, both public and private well finally help biotech in Japan start living up to its scientific potential. https://lnkd.in/g_cj2_ek

At the dawn of 2024, there’s a sense of renewed optimism in the biotech sector despite recent sector-specific challenges. This week, the J.P. Morgan Health Care Conference witnessed strong deal-making activity. Here's how #Biotech bounces back at JPM 2024: https://lnkd.in/eNsKYR7N #ObesityDrugs #AntibodyDrugs #funding #RandD #ClinicalDevelopment #biotechnology #oncology

Valerio Therapeutics S.A., a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics, announced the acquisition of Emglev Therapeutics, a spinoff of Institut Curie, one of France’s leading cancer centers. Valour Bio has been established as a wholly owned subsidiary of Valerio Therapeutics to focus on discovering single domain antibodies (sdAbs) as drug and radio conjugates, bispecific T-cell engagers, blocking and binding sdAbs, or CAR-T sdAb drug candidates for multiple therapeutic areas. Emglev’s proprietary synthetic sdAb libraries overcome the current barriers of conventional antibody discovery by providing unique targets and selecting humanized or fully human sdAbs entirely in vitro. These sdAbs are validated for a wide array of therapeutic applications, offering a distinct advantage in antibody development. Shefali Agarwal, Christelle Masdeu, Sandrine Moutel, Cécile Campagne Read more - https://lnkd.in/gTXrQcJX To share your startup story write us on - contact@startuprise.co.uk #valerio #Emglev #acqusisition #Biotech #news #startup

Bolt Biotherapeutics is halting its lead cancer drug BDC-1001, laying off 50% of staff, and shifting focus to early-stage candidates BDC-3042 (Phase 1) and BDC-4182 (preclinical). Key Insights - ▪️ New Direction: Prioritizing innovative ISAC technology for anti-tumor responses. ▪️ Partnerships: Continued ISAC research supported by Genmab and Toray. ▪️ Leadership Change: Willie Quinn steps in as CEO. ▪️ Impact: Changes aim to extend cash runway into 2026; stock dropped 34%. Questions - ▪️ How will this strategic shift impact Bolt’s future? ▪️ Can ISAC technology succeed despite high risks? ▪️ What does this mean for cancer drug innovation? #Biotech #CancerResearch #ISAC #BoltBiotherapeutics

🌟 Discover the Swiss Biotech Revolution! Switzerland isn't just about chocolates and stunning landscapes—it's a powerhouse of biotech innovation! 🚀 From groundbreaking cancer treatments to regenerative medicine, Swiss startups are leading the charge. Dive into this latest article featuring 18 Swiss biotech companies that are transforming the future of healthcare. 🌍💉 #rare #raredisease #rarediseases #healthcare #biotech #pharma #pharmaceuticals #Switzerland #lifescience

🕺 DISCO Pharmaceuticals GmbH launches with €20 Million Seed Financing! 🚀 🔬 Based out of Germany & Switzerland, DISCO are unravelling the surfaceome of cancer cells on a large scale, uncovering novel targets and pioneering the development of ground-breaking, first-in-class drugs. 💸 The financing is backed by a prominent investor syndicate, which includes Panakes Partners, M Ventures , AbbVie Ventures, with Sofinnova Partners spearheading the financing. 🗣 "𝘞𝘦 𝘣𝘦𝘭𝘪𝘦𝘷𝘦 𝘵𝘩𝘢𝘵 𝘰𝘶𝘳 𝘴𝘶𝘳𝘧𝘢𝘤𝘦𝘰𝘮𝘦 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘪𝘴 𝘵𝘳𝘶𝘭𝘺 𝘥𝘪𝘴𝘳𝘶𝘱𝘵𝘪𝘷𝘦 𝘢𝘯𝘥 𝘸𝘪𝘭𝘭 𝘵𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘰𝘱𝘵𝘪𝘰𝘯𝘴 𝘢𝘯𝘥 𝘶𝘭𝘵𝘪𝘮𝘢𝘵𝘦𝘭𝘺 𝘪𝘮𝘱𝘳𝘰𝘷𝘦 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴." Roman Thomas ▶ 2024 has kicked off in excellent fashion, long may the good news continue! Check out the link posted below to learn more about DISCO Pharmaceuticals GmbH - congratulations to all involved. #biotech #drugdiscovery #proteomics #surfaceome